220 related articles for article (PubMed ID: 36810815)
1. A review of JAK and IL-23 inhibitors to treat vitiligo.
Lee H; Cowan TL; Daniel BS; Murrell DF
Australas J Dermatol; 2023 May; 64(2):204-212. PubMed ID: 36810815
[TBL] [Abstract][Full Text] [Related]
2. Biologic and targeted therapeutics in vitiligo.
Karagaiah P; Schwartz RA; Lotti T; Wollina U; Grabbe S; Goldust M
J Cosmet Dermatol; 2023 Jan; 22(1):64-73. PubMed ID: 35029034
[TBL] [Abstract][Full Text] [Related]
3. Vitiligo: an update on systemic treatments.
Searle T; Al-Niaimi F; Ali FR
Clin Exp Dermatol; 2021 Mar; 46(2):248-258. PubMed ID: 33350506
[TBL] [Abstract][Full Text] [Related]
4. Bridging Molecular Mechanism and Clinical Practice in Vitiligo Treatment: An Updated Review.
Ju HJ; Bae JM
Dermatology; 2024; 240(3):474-486. PubMed ID: 38417409
[TBL] [Abstract][Full Text] [Related]
5. Different Advanced Therapeutic Approaches to Treat Vitiligo.
Sharma CK; Sharma M; Aggarwal B; Sharma V
J Environ Pathol Toxicol Oncol; 2015; 34(4):321-34. PubMed ID: 26756425
[TBL] [Abstract][Full Text] [Related]
6. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
Phan K; Phan S; Shumack S; Gupta M
J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
[TBL] [Abstract][Full Text] [Related]
7. Vitiligo: an update on current pharmacotherapy and future directions.
Colucci R; Lotti T; Moretti S
Expert Opin Pharmacother; 2012 Sep; 13(13):1885-99. PubMed ID: 22835073
[TBL] [Abstract][Full Text] [Related]
8. Vitiligo: An Updated Narrative Review.
Leung AKC; Lam JM; Leong KF; Hon KL
Curr Pediatr Rev; 2021; 17(2):76-91. PubMed ID: 33302860
[TBL] [Abstract][Full Text] [Related]
9. Topical treatment and combination approaches for vitiligo: new insights, new developments.
Hossani-Madani AR; Halder RM
G Ital Dermatol Venereol; 2010 Feb; 145(1):57-78. PubMed ID: 20197746
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study.
Cavalié M; Ezzedine K; Fontas E; Montaudié H; Castela E; Bahadoran P; Taïeb A; Lacour JP; Passeron T
J Invest Dermatol; 2015 Apr; 135(4):970-974. PubMed ID: 25521460
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for the treatment of vitiligo.
Karagaiah P; Valle Y; Sigova J; Zerbinati N; Vojvodic P; Parsad D; Schwartz RA; Grabbe S; Goldust M; Lotti T
Expert Opin Emerg Drugs; 2020 Mar; 25(1):7-24. PubMed ID: 31958256
[No Abstract] [Full Text] [Related]
12. Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors.
Cunningham KN; Rosmarin D
Am J Clin Dermatol; 2023 Mar; 24(2):165-186. PubMed ID: 36715849
[TBL] [Abstract][Full Text] [Related]
13. The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non-segmental vitiligo.
Yousefian F; Yadlapati S; Browning JC
J Cosmet Dermatol; 2023 Mar; 22(3):1105-1107. PubMed ID: 36440703
[TBL] [Abstract][Full Text] [Related]
14. The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo.
Ju HJ; Han JH; Kim MS; Lee SH; Shin JW; Choi M; Jeong KH; Han TY; Choi CW; Lee HJ; Oh SH; Lee SH; Kim DH; Shin J; Lee JH; Kim SS; Kang HY; Chang SE; Kim JS; Lee DY; Choi GS; Suh DH; Chan Kim Y; Park CJ; Kim KH; Lee AY; Chan Park K; Lee MH; Bae JM;
J Am Acad Dermatol; 2021 Jun; 84(6):1619-1627. PubMed ID: 33508387
[TBL] [Abstract][Full Text] [Related]
15. Vitiligo treatment update.
Daniel BS; Wittal R
Australas J Dermatol; 2015 May; 56(2):85-92. PubMed ID: 25495880
[TBL] [Abstract][Full Text] [Related]
16. Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics.
Pala V; Ribero S; Quaglino P; Mastorino L
J Clin Med; 2023 Dec; 12(23):. PubMed ID: 38068541
[TBL] [Abstract][Full Text] [Related]
17. Topical ruxolitinib: A new treatment for vitiligo.
Tavoletti G; Avallone G; Conforti C; Roccuzzo G; Maronese CA; Mattioli MA; Quaglino P; Zalaudek I; Marzano AV; Ribero S; Alberti-Violetti S
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2222-2230. PubMed ID: 37147856
[TBL] [Abstract][Full Text] [Related]
18. Disorders of Hypopigmentation.
Dina Y; McKesey J; Pandya AG
J Drugs Dermatol; 2019 Mar; 18(3):s115-s116. PubMed ID: 30909355
[TBL] [Abstract][Full Text] [Related]
19. Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis.
Dang YP; Li Q; Shi F; Yuan XY; Liu W
Dermatol Ther; 2016; 29(2):126-33. PubMed ID: 26460804
[TBL] [Abstract][Full Text] [Related]
20. Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis.
Li R; Qiao M; Wang X; Zhao X; Sun Q
Photodermatol Photoimmunol Photomed; 2017 Jan; 33(1):22-31. PubMed ID: 27696531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
